	US 11,946,051 B2
	Composition for preventing or treating keloids or hypertrophic scars
Saewha Jeon, Seoul (KR); Ho Yun Chung, Daegu (KR); Na Ra Oh, Seoul (KR); Yun Hee Kim, Seoul (KR); Jikhyon Han, Seoul (KR); and Hyun Ah Moon, Seoul (KR)
Assigned to Tego Science Inc., Seoul (KR)
Filed by Tego Science Inc., Seoul (KR)
Filed on Nov. 21, 2022, as Appl. No. 17/990,757.
Application 17/990,757 is a division of application No. 16/639,760, abandoned, previously published as PCT/KR2019/017039, filed on Dec. 4, 2019.
Claims priority of application No. 10-2019-0117157 (KR), filed on Sep. 24, 2019.
Prior Publication US 2023/0124032 A1, Apr. 20, 2023
Int. Cl. C07H 21/02 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 31/7105 (2013.01); A61K 31/713 (2013.01); G01N 33/6881 (2013.01); G01N 33/6893 (2013.01); C12N 2310/14 (2013.01); G01N 2500/04 (2013.01); G01N 2800/20 (2013.01)]

1 Claim

1. A method of treating a subject having hypertrophic scar, comprising:

(a) administering a pharmaceutical composition, which comprises, as an active ingredient, siRNA that inhibits the expression of gene encoding PRRC1, wherein the siRNA is selected from the group consisting of SEQ ID NO: 3/SEQ ID NO: 4 and SEQ ID NO: 5/SEQ ID NO: 6, to the subject having hypertrophic scar.